Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 2
Release Date: 05/28/2026
Post-Traumatic Headache in Children and Genetic Risk of Migraine
Neurology Minute
Dr. Jessica Ailani and Dr. Serena Orr discuss the genetic risk of migraine and post-traumatic headache in children. Show citation: Orr SL, Hershey AD, Kurowski BG, et al. Post-Traumatic Headache in Children and Genetic Risk of Migraine: An Observational Cohort Study. Neurol Genet. 2026;12(2):e200371. Published 2026 Apr 1. doi:
info_outline
Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis
Neurology Minute
Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis. Show citation: Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:
info_outline
Negative Myoclonus
Neurology Minute
Dr. Zohaib Siddiqi shares clinical pearls on negative myoclonus.
info_outline
An Update on Troriluzole
Neurology Minute
Dr. Margarita Fedorova discusses the use of troriluzole for spinocerebellar ataxia. Show citations:
info_outline
The Current State of Diagnostics for Neuroimmunologic Disorders in Africa
Neurology Minute
Drs. Paul Crane, Fiifi Duodu, and Malya Sahu discuss neuroimmunology and multiple sclerosis diagnosis in Africa, including challenges and efforts to improve care. Show citation: Sahu M, Chomba M, Duodu F, Diaz MM, Sokhi D, Saylor D. The Current State of Diagnostics for Neuroimmunological Disorders in Africa. J Cent Nerv Syst Dis. 2025;17:11795735251385319. Published 2025 Nov 19. doi:
info_outline
Ampreloxetine for Neurogenic Orthostatic Hypotension in MSA
Neurology Minute
Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions. Show citation: Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:
info_outline
Sex Differences in Levodopa Pharmacokinetics in Early Parkinson Disease
Neurology Minute
Dr. Margarita Fedorova explores sex-related differences in the pharmacokinetics of levodopa among levodopa-naïve patients with PD and evaluates their relationships with levodopa-related complications. Show citation: Conti V, De Bellis E, Corbi G, et al. Sex differences in levodopa pharmacokinetics in early Parkinson's disease: implications on levodopa-related complications. Front Pharmacol. 2026;17:1748932. Published 2026 Apr 7. doi:
info_outline
Psychiatric Comorbidities in Epilepsy - Part 2
Neurology Minute
In part two of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the steps to take if you are screening for a psychiatric comorbidity and the results indicate that someone may be positive for depression, anxiety, or another condition. Show citations: Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi: Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017...
info_outline
August 2026 President Spotlight: How We’re Working with the AMA
Neurology Minute
In the August episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost highlight how the AAN’s growing representation within the AMA strengthens the voice of neurology. Stay informed by watching the .
info_outline
Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 2
Neurology Minute
In part two of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the FENhance 1 and 2 trials looking at fenebrutinib in relapsing MS. For more information, please read about the abstract that was presented at the . Read more about the .
info_outlineIn the second episode of this series, Dr. Tesha Monteith and Dr. Peter Goadsby discuss the prediction of treatment responses for personalized medicine.
Show transcript:
Dr. Tesha Monteith:
Hi, this is Tesha Monteith with The Neurology Minute. Today I'm speaking with Peter Goadsby from the Division of Biomedical Sciences at King Abdullah University of Science and Technology about key trends in headache medicine and some of the most impactful research presented at the AAN annual meeting. Can you talk a little bit about prediction of treatment response for personalized medicine?
Dr. Peter Goadsby
I hope that AI gives us some direction. I haven't seen anything yet, but I don't think we've done enough with it to make it stunning yet. I think that the AI systems ... I'd love to know, for example ... I've been using triptans for 30 years and apart from using sumatriptan first when [inaudible 00:00:51] had a triptan simply because it's the commonest triptan, which is generally what I do, that's a pretty naff rule when you think about it. I'd like to think that AI systems could work out where we should be going in terms of acute therapy, preventive therapy, whether there are particular red flags or amber flags you might say in a person's broad history. I don't think we've got there yet, but I actually think we will get there. I think we'll be surprised and we'll learn things about the biology of the disorder and about the pharmacology of these medicines, which must have subtle differences because we all see people who respond to one and don't respond to another, and you sort of scratch your head, but you're happy that it happens.
Dr. Tesha Monteith:
I agree with you, and I think the future is really bright for headache medicine and the potential of AI to move the needle. Peter, thank you again for joining us and sharing your insights. I really appreciate you being on. This is Tesha Monteith. Thank you for listening to The Neurology Minute.